Halozyme Therapeutics, Inc. (HALO): Cost of Revenue
$228.77M
Year ended 2025-12-31
$292.42M
Trailing 12 months to 2026-06-30
+18.0%
3-year compound annual growth
+39.5%
5-year compound annual growth
+22.8%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $228.77M | +43.5% | 2026-02-17, From 2025-01-01 |
| 2024-12-31 | $159.42M | -17.1% | 2026-02-17, From 2024-01-01 |
| 2023-12-31 | $192.36M | +38.1% | 2026-02-17, From 2023-01-01 |
| 2022-12-31 | $139.30M | +71.1% | 2025-02-18, From 2022-01-01 |
| 2021-12-31 | $81.41M | +87.7% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $43.37M | -4.8% | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $45.55M | +349.3% | 2022-02-22, From 2019-01-01 |
| 2018-12-31 | $10.14M | -67.5% | 2021-02-23, From 2018-01-01 |
| 2017-12-31 | $31.15M | -6.2% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $33.21M | +13.5% | 2019-02-21, From 2016-01-01 |
| 2015-12-31 | $29.25M | +28.7% | 2018-02-20, From 2015-01-01 |
| 2014-12-31 | $22.73M | +263.9% | 2017-02-28, From 2014-01-01 |
| 2013-12-31 | $6.25M | +470.9% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $1.09M | +324.3% | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $257.8K | -73.8% | 2014-02-28, From 2011-01-01 |
| 2010-12-31 | $985.3K | +215.9% | 2013-03-01, From 2010-01-01 |
| 2009-12-31 | $311.9K | n/a | 2012-03-12, From 2009-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $228.77M | +43.5% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $415.97M | -3.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $73.04M | -64.0% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $868.00M | -40.7% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $790.50M | -21.8% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $19.07M | +55.5% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $83.70M | +9.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $352.01M | -2.2% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $52.10M | +53.2% |
Compare HALO, TECH, NVAX, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗